Q1 Earnings Estimate for Neurogene Issued By Leerink Partnrs

Neurogene Inc. (NASDAQ:NGNE) – Research analysts at Leerink Partnrs issued their Q1 2025 earnings per share estimates for Neurogene in a report issued on Monday, March 24th. Leerink Partnrs analyst M. Foroohar anticipates that the company will post earnings per share of ($1.12) for the quarter. The consensus estimate for Neurogene’s current full-year earnings is ($4.27) per share. Leerink Partnrs also issued estimates for Neurogene’s Q2 2025 earnings at ($1.18) EPS, Q3 2025 earnings at ($1.19) EPS, Q4 2025 earnings at ($1.27) EPS, FY2025 earnings at ($4.76) EPS and FY2026 earnings at ($6.03) EPS.

NGNE has been the subject of a number of other research reports. HC Wainwright cut their price objective on Neurogene from $55.00 to $50.00 and set a “buy” rating for the company in a research report on Tuesday. William Blair reaffirmed an “outperform” rating on shares of Neurogene in a research report on Tuesday. Seven research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $59.80.

Neurogene Price Performance

NGNE stock opened at $14.52 on Thursday. The firm has a market cap of $215.69 million, a PE ratio of -3.40 and a beta of 1.01. Neurogene has a 12 month low of $13.47 and a 12 month high of $74.49. The firm has a 50 day simple moving average of $16.88 and a 200 day simple moving average of $28.82.

Neurogene (NASDAQ:NGNE) last posted its quarterly earnings data on Monday, March 24th. The company reported ($0.99) earnings per share for the quarter, beating the consensus estimate of ($1.04) by $0.05. The business had revenue of $0.93 million for the quarter.

Insiders Place Their Bets

In related news, CFO Christine Mikail Cvijic sold 4,501 shares of the business’s stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $16.94, for a total value of $76,246.94. Following the completion of the sale, the chief financial officer now owns 72,343 shares of the company’s stock, valued at approximately $1,225,490.42. The trade was a 5.86 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Insiders own 9.92% of the company’s stock.

Hedge Funds Weigh In On Neurogene

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. PNC Financial Services Group Inc. bought a new stake in Neurogene in the fourth quarter worth approximately $71,000. China Universal Asset Management Co. Ltd. acquired a new stake in shares of Neurogene in the 4th quarter valued at $72,000. Virtus ETF Advisers LLC lifted its stake in shares of Neurogene by 45.1% in the 4th quarter. Virtus ETF Advisers LLC now owns 3,183 shares of the company’s stock valued at $73,000 after purchasing an additional 989 shares during the last quarter. BNP Paribas Financial Markets boosted its holdings in Neurogene by 192.8% in the third quarter. BNP Paribas Financial Markets now owns 2,170 shares of the company’s stock worth $91,000 after purchasing an additional 1,429 shares in the last quarter. Finally, Wells Fargo & Company MN increased its position in Neurogene by 34.5% during the fourth quarter. Wells Fargo & Company MN now owns 5,444 shares of the company’s stock worth $124,000 after buying an additional 1,397 shares during the last quarter. Institutional investors own 52.37% of the company’s stock.

Neurogene Company Profile

Neurogene Inc, a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease.